Participated · Series A · Nov 2025

IBI Ag is an Israeli agri-biotech company pioneering a platform that uses single-domain antibodies (nanobodies) to create highly selective biological insecticides. Adapted from human therapeutics and optimized for agriculture, its products introduce new modes of action that protect high-value crops from both sucking and chewing pests while sparing beneficial species. The firm positions its technology as a lower-ecological-footprint alternative to conventional chemicals, aiming to help farmers boost yields sustainably. With fresh Series A capital, IBI Ag plans to accelerate product development and advance regulatory filings on multiple bio-insecticide candidates. The company also intends to deepen its collaboration with strategic investor Corteva to speed commercialization. Founded by The Trendlines Group alongside Dr. Amir Ayali and Dr. Rony Oren Benaroya, IBI Ag has been supported by the Israel Innovation Authority since inception. Financial details beyond the recent $10 million raise were not disclosed.

Participated · Seed · Dec 2024

Celleste Bio develops cell-cultured cocoa ingredients using a proprietary combination of BioTech, AgTech and computational AI to grow 100% natural cocoa from one or two beans in controlled, year‑round conditions. The company was founded in 2022 and positions its technology as a response to cocoa supply challenges driven by climate change and conventional farming. Celleste intends to pilot and scale production of its cell‑cultured cocoa ingredients and build the infrastructure and technological capabilities needed for commercial readiness. The seed financing will be used to accelerate R&D, expand infrastructure, and advance technological development. The company frames its mission as creating an economically and environmentally sustainable cocoa supply and has support from The Trendlines Group.

Participated · Series A · Feb 2024

Vessi Medical has developed an IP-protected cryospray system purposely designed for hollow and humid organs as a novel, minimally invasive approach to treat non-muscle-invasive bladder cancer (NMIBC). The technology is positioned as an alternative to the invasive first-line therapy TURBT and has been used in a first-in-human study. Led by Founder and CEO Eyal Kochavi, the company aims to reduce side effects, improve patient outcomes, and lower healthcare costs relative to current surgical approaches. Vessi plans to use new funding to expand R&D capabilities and support clinical studies in Israel and the U.S. The company is also pursuing regulatory clearance to bring its treatment to patients and physicians. Vessi Medical develops an intravesical cryotherapy system for superficial (non‑muscle invasive) bladder cancer. Its core product is a minimally invasive system composed of a standalone console and a disposable device inserted transurethrally into the bladder. The company is led by CEO Eyal Kochavi and is advancing the technology to improve quality of life for NMIBC patients. Vessi raised $1.7M in funding to continue development of its device. The proceeds are intended to support the planned first‑in‑human study to demonstrate safety and efficacy in Q1 2021.

Participated · Equity · Sep 2023

ViAqua Therapeutics develops an orally administered RNA-particle platform designed to prevent diseases in aquaculture species. Its first product is a feed supplement to enhance shrimp resistance to viral infections, initially targeting White Spot Virus (WSSV). The company says the solution will provide production stability for farmers and enable increased production per farm without raising disease risk. ViAqua intends to use the new funding to bring its first product to market and to invest in R&D for future products. The company plans to begin production in India at the beginning of 2024 and has a joint development and marketing agreement with Skretting, a Nutreco company. The company is led by CEO Shai Ufaz and is based in Haifa, Israel. ViAqua Therapeutics develops an orally administered RNA-particle platform using RNA and an encapsulated delivery method to promote shrimp and aquatic animal health, including protection against viral challenges. The company is commercializing its first shrimp health product and plans to develop additional products for aquatic animal health and nutrition. ViAqua intends to use the recent funding to support that commercialization and further product development. The company is led by CEO Shai Ufaz and is based in Misgav, Israel. The platform targets prevalent and devastating viral diseases in shrimp through orally delivered RNA particles.

Participated · Equity · Feb 2022

Vensica Medical is a urology therapeutics company developing a proprietary needle-free delivery system for Xeomin® (botulinum toxin A) aimed at treating overactive bladder (OAB). The company’s platform is intended to provide a minimally invasive, needle-less alternative for delivering botulinum toxin A. Vensica plans to use newly raised capital to accelerate upcoming Phase 2 clinical trials across the United States and Europe. As part of a strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic applications in several urologic indications and will receive Merz’s clinical development support. The company was established in the incubator program of The Trendlines Group and The Israel Innovation Authority and maintains an office in Herzliya, Israel. Leadership includes CEO Avner Geva and CTO Avi Eftel. Vensica is a clinical-stage biopharmaceutical company developing a proprietary ultrasound-assisted drug delivery platform for urological indications including overactive bladder, neurogenic bladder, and interstitial cystitis. The company has an exclusive arrangement with Merz Therapeutics to use Merz’s botulinum neurotoxin A (Xeomin®) for needle-free urological procedures. Vensica plans to use the new funding to conduct phase II multicenter clinical trials in Europe and the USA. It also intends to expand its workforce in Israel to support clinical and regulatory development of its device in collaboration with Merz. Vensica was founded in 2015 by Avner Geva and is based in Tel Aviv, Israel. The company is in the clinical development stage and is advancing its device and combination product toward later-stage trials. Vensica Medical is developing VensiCare, an ultrasound-based, needle-free drug-delivery system whose initial indication is delivery of botulinum toxin to treat overactive bladder (OAB). The company also holds intellectual property for delivering oncology agents to the bladder. Led by CEO Avner Geva, Vensica plans to commence human clinical trials of VensiCare for OAB in the fourth quarter of 2018. Vensica received a $2M investment from Cogentix Medical. Cogentix will take one seat on Vensica’s board and received options to acquire the entire company for an additional $8M. Cogentix is a global medical device company (NASDAQ: CGNT) focused on the Urology, Uro/Gyn and Gynecology markets.